Skip to main content
Graphik Bartzsch MRTgH2AX_1 Bild2a
Helmholtz Munich | ©Bartzsch

Molecular Targets and Therapeutics Center Institute of Radiation Medicine

The Institute of Radiation Medicine (IRM) at Helmholtz Munich encompasses all aspects of modern radiation research, with a focus on translational issues and clinical applications.
Our highly interdisciplinary team, comprising physicists, biologists, medical doctors, and engineers, aims to integrate preclinical knowledge, theoretical modeling, and clinical practice in the field of Clinical and Experimental Radiation Oncology, with a particular emphasis on radiotherapy research.
The IRM is closely associated with the Department of Radiation Oncology and Radiotherapy at the Klinikum rechts der Isar (TU München) as well as the German Consortium for Translational Cancer Research (DKTK) at its partner location in Munich.

The Institute of Radiation Medicine (IRM) at Helmholtz Munich encompasses all aspects of modern radiation research, with a focus on translational issues and clinical applications.
Our highly interdisciplinary team, comprising physicists, biologists, medical doctors, and engineers, aims to integrate preclinical knowledge, theoretical modeling, and clinical practice in the field of Clinical and Experimental Radiation Oncology, with a particular emphasis on radiotherapy research.
The IRM is closely associated with the Department of Radiation Oncology and Radiotherapy at the Klinikum rechts der Isar (TU München) as well as the German Consortium for Translational Cancer Research (DKTK) at its partner location in Munich.

Research Groups

Helmholtz Munich | © Raulefs
Combs Group

Personalized RadioOncology

Radiotherapy is an important treatment modality for cancer patients. About 40-50% of all cancer patients are treated with radiotherapy. We are investigating therapy response and aiming to identify biomarkers for adjusting the appropriate irradiation strategy, including application of the proper radiation dose and potential occurrence of adverse side effect. This personalized radiotherapy concept will guide future patient stratification.

Bild Schmid group Radiobiology IRM
© Helmholtz Munich I Schmid
Schmid Group

Radiobiology

Our radiobiology research group investigates the use of novel radiation modalities for improving radiation therapy. Spatial fractionated radiotherapy include Microbeam Radiation Therapy (MRT) and Minibeam Radiation Therapy (MBRT) - two innovative, but still preclinical concepts in radiation therapy. FLASH radiotherapy is a novel technique, involving treatment of tumors at ultra-high dose rates, which reduced the damage to healthy tissue surrounding the tumor. Our main interest is the understanding of the underlying biomedical mechanisms of spatially fractionated and high dose rate (“FLASH”) radiation therapy. The final aim of our research is the translation of these highly innovative techniques into clinical application.

Graphik Petrich weiss
Helmholtz Munich I © Petrich
Bartzsch Group

Experimental Medical Physics

How can we reduce the toxicity of radiation therapy? This question is our driving motivation in the Experimental Medical Physics team. We investigate the next generation radiation oncology modalities that reduce side effects. Our current focus is spatially fractionated and high dose rate (“FLASH”) radiation therapy. We develop and test new radiotherapy equipment, such as an innovative x-ray source, model radiobiological and radiochemical effects with mathematical tools, and simulate and plan treatments with novel, experimental strategies on clinical data. The aim of our interdisciplinary team is the translation of promising research results into clinical application.

HMGU Image_Peeken
Helmholtz Munich I © Peeken
Peeken Group

Artificial Intelligence and Radiomics in Radiation Oncology

Medical imaging plays an essential role at multiple steps in the workflow of Radiation Oncology. In our group, we are investigating the value of artificial intelligence-based medical image analysis for non-invasive tumor characterization, better prognostic assessment, improved tumor detection, and automated treatment planning. This way we aim for improved personalization of cancer care.

Graphik Dobiasch group
Helmholtz Munich I ©Dobiasch
Dobiasch Group

Personalized Radiooncology of Pancreatic Cancer

Pancreatic cancer is one of the most aggressive and lethal human tumors. Therefore, experimental stratification of radiation response and combination with targeted therapies are investigated in preclinical pancreatic cancer models within the framework of translational research. Different in vitro approaches (patient-derived organoids, murine, and human cell lines), as well as innovative high-precision irradiation concepts in advanced tumor mouse models, are established. The major aim is the generation of novel treatment options for pancreatic cancer patients to realize a true personalized medicine and improve clinical outcome.

Our Scientists at Radiation Medicine

Mitarbeiterfoto Thomas Schmid IRM

Prof. Dr. Thomas Schmid

Deputy Director Group Leader Radiobiology View profile
Stefan Bartzsch

PD Dr. Stefan Bartzsch

Group Leader Experimental Medical Physics View profile
Susanne Raulefs

Dr. Susanne Raulefs

Scientific Manager
Mitarbeiterfoto Daniela Schilling IRM

Dr. Daniela Schilling

Scientific Manager
Mitarbeiterfoto Sophie Dobiasch IRM

PD Dr. Sophie Dobiasch

Junior Group Leader Personalized Radiooncology of pancreatic cancer View profile

Publications of Our Institute

Read more

Networks and Affiliations

TUM Logo sRGB
Logo UniBw
DEGRO-Logo vertikal

Contact

Susanne Raulefs

Dr. Susanne Raulefs

Scientific Manager

Building 57, Room 144